Richard Kefford


  • 27134 Citations
  • 73 h-Index
1980 …2023
If you made any changes in Pure these will be visible here soon.

Personal profile


Professor Richard Kefford AM MB BS PhD FRACP is Professor of Cancer Medicine and Head, Department of Clinical Medicine at Macquarie University, Sydney and Co-Director of Research at Melanoma Institute Australia. He is an internationally acclaimed melanoma researcher and a national leader in academic medicine and medical research with a life-long record of commitment and service to Australian medical research, peer review, professional training and mentoring and community education in oncology. He contributed to the mapping and characterisation of the major melanoma susceptibility genes and the development of international guidelines on genetic testing of those at high melanoma risk. He played a pivotal role in the development of life-extending drug treatments now used as standard-of-care for melanoma, including the first-time in human trial of dabrafenib, the pioneering use of dabrafenib and trametinib for patients with brain metastases, and the Phase 1 clinical trial of pembrolizumab.

Fingerprint Fingerprint is based on mining the text of the person's scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 2 Similar Profiles
Melanoma Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Mutation Medicine & Life Sciences
Survival Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Neoplasm Metastasis Medicine & Life Sciences
Mitogen-Activated Protein Kinase Kinases Medicine & Life Sciences
Tumor Suppressor Protein p14ARF Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2014 2023

Centre for Research Excellence in Implementation Science in Oncology (CRE-ISO)

Braithwaite, J., Ward, R., Currow, D., Delaney, G., Kefford, R., Olver, I., Karnon, J., Crowe, P., Liauw, W., Westbrook, J., Meiser, B., Tieman, J., Verspoor, K., Ellis, L., Krishnasamy, M., Ayliff, N., Hawkins, N., Hibbert, P., Farnsworth, R. & Clay-Williams, R.


Project: Other

Acquired resistance to PD1 inhibition in melanoma

Rizos, H., Carlino, M., Kefford, R., Zhang, X. D., Menzies, A. M., Long, G., McGuire, H., Yang, J., Scolyer, R. & De St Groth, B. F.

1/01/17 → …

Project: Research

Research Outputs 1980 2019

Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1 based immunotherapy

Lim, S. Y., Lee, J. H., Nur Gide, T., Menzies, A. M., Guminski, A., Carlino, M. S., Breen, E., Yang, J. Y. H., Ghazanfar, S., Kefford, R. F., Scolyer, R. A., Long, G. V. & Rizos, H., Mar 2019, In : Clinical Cancer Research. 25, 5, p. 1557-1563 7 p.

Research output: Contribution to journalArticleResearchpeer-review

Confidence Intervals

Distinct molecular profiles and immunotherapy treatment outcomes of V600E and V600K BRAF-mutant melanoma

da Silva, I. P., Wang, K. Y. X., Wilmott, J. S., Holst, J., Carlino, M. S., Park, J. J., Quek, C., Wongchenko, M., Yan, Y., Mann, G., Johnson, D. B., McQuade, J. L., Rai, R., Kefford, R. F., Rizos, H., Scolyer, R. A., Yang, J. Y. H., Long, G. V. & Menzies, A. M., 15 Feb 2019, In : Clinical Cancer Research. 25, 4, p. 1272-1279 8 p.

Research output: Contribution to journalArticleResearchpeer-review

MAP Kinase Signaling System
Dual Specificity Phosphatase 6

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W. J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R., Weber, J. S., Dronca, R., Mitchell, T. C., Patnaik, A., Zarour, H. M., Joshua, A. M., Zhao, Q., Jensen, E., Ahsan, S., Ibrahim, N. & Ribas, A., 1 Apr 2019, In : Annals of oncology : official journal of the European Society for Medical Oncology. 30, 4, p. 582-588 7 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
Disease-Free Survival

Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial

Long, G. V., Saw, R. P. M., Lo, S., Nieweg, O. E., Shannon, K. F., Gonzalez, M., Guminski, A., Lee, J. H., Lee, H., Ferguson, P. M., Rawson, R. V., Wilmott, J. S., Thompson, J. F., Kefford, R. F., Ch'ng, S., Stretch, J. R., Emmett, L., Kapoor, R., Rizos, H., Spillane, A. J. & 2 othersScolyer, R. A. & Menzies, A. M., 3 Jun 2019, In : The Lancet Oncology.

Research output: Contribution to journalArticleResearchpeer-review

Neoadjuvant Therapy

Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF V600E or BRAF V600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial

Schadendorf, D., Hauschild, A., Santinami, M., Atkinson, V., Mandalà, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., Robert, C., Mortier, L., Lesimple, T., Plummer, R., Schachter, J., Dasgupta, K., Manson, S., Koruth, R., Mookerjee, B., Kefford, R. & 3 othersDummer, R., Kirkwood, J. M. & Long, G. V., 1 May 2019, In : The Lancet Oncology. 20, 5, p. 701-710 10 p.

Research output: Contribution to journalArticleResearchpeer-review

Quality of Life